Robotic Cardiology Surgery Market Report 2025

This robotic cardiology surgery market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The robotic cardiology surgery market size has grown rapidly in recent years. It will grow from $0.72 billion in 2024 to $0.84 billion in 2025 at a compound annual growth rate (CAGR) of 16.7%. The growth in the historic period can be attributed to rising adoption of robotic surgery in cardiology, growing preference for minimally invasive surgical procedures, rising incidence of cardiovascular diseases, growing healthcare expenditures, and growing aging population.

The robotic cardiology surgery market size is expected to see rapid growth in the next few years. It will grow to $1.54 billion in 2029 at a compound annual growth rate (CAGR) of 16.5%. The growth in the forecast period can be attributed to increasing investment in advanced medical technologies, increasing telemedicine and remote surgery, rising number of surgical procedures, increasing prevalence of chronic diseases, and favorable regulatory environments, and the availability of reimbursement policies. Major trends in the forecast period include integration of artificial intelligence (AI) and machine learning algorithms, innovations in robotic technology, miniaturizing robotic components, product innovations, integrating 3D visualization, and incorporating features like motion scaling, and tremor filtering.

The rising prevalence of cardiovascular diseases is expected to drive the growth of the robotic cardiology surgery market in the coming years. Cardiovascular disease (CVD) refers to a group of conditions affecting the heart or blood vessels. The increase in CVD cases is attributed to factors such as lifestyle choices, medical conditions, genetic predispositions, and environmental influences. Robotic cardiology surgery plays a vital role in advancing the treatment of these diseases by offering safer, more precise, and minimally invasive surgical options, leading to improved patient outcomes and higher quality care. For example, in December 2023, data from the Australian Institute of Health and Welfare, a government agency, revealed that doctor-certified deaths from coronary heart disease (CHD) rose from 14,100 in 2021 to 14,900 in 2022. Therefore, the rise in cardiovascular diseases is fueling the growth of the robotic cardiology surgery market.

Major companies in the robotic cardiology surgery sector are concentrating on creating innovative surgical solutions, including proof-of-concept robotic procedures, to improve precision in cardiac interventions, reduce invasiveness, and enhance patient outcomes through advanced technology and real-time analytics. A proof-of-concept robotic procedure is a pioneering technique designed for implanting an aortic valve replacement using a minimally invasive method, after successful trials on cadaver models. For example, in March 2024, CardioPrecision Ltd., a UK-based company specializing in robotic surgeries, introduced proof-of-concept robotic procedures for minimally invasive aortic valve replacement, following successful cadaver trials. This robotic system improves precision and control during surgery, enabling surgeons to perform with greater accuracy and potentially increasing the overall success rate of the procedure. The minimally invasive nature of this approach is crucial as it can reduce pain, minimize blood loss, and lower the risk of infection, leading to faster patient recovery.

In August 2022, Medtronic plc, an Ireland-based manufacturer of medical devices, acquired Affera Inc. for an undisclosed sum. This acquisition is intended to enhance Medtronic's capabilities in cardiac interventions, bolster its standing in the competitive cardiology market, and meet the rising demand for advanced medical solutions. Affera Inc., a US-based firm, specializes in electrophysiology technologies, including robotic systems utilized in cardiac procedures.

Major companies operating in the robotic cardiology surgery market are Abbott Laboratories, Medtronic PLC, Siemens Healthineers AG, Boston Scientific Corporation, Edwards Lifesciences Corporation, Smith & Nephew PLC, KARL STORZ SE & Co. KG, Renishaw PLC, Think Surgical Inc., Terumo Corporation, CMR Surgical limited, Corindus Vascular Robotics Inc., XACT Robotics Ltd., Titan Medical Inc., Asensus Surgical Inc., Intuitive Surgical Inc., Aurora Surgical Robotics Inc., Precision Robotics Ltd., SS Innovations International Inc., Hansen Medical Inc.

North America was the largest region in the robotic cardiology surgery market in 2024. The regions covered in the robotic cardiology surgery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the robotic cardiology surgery market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Robotic cardiology surgery is a minimally invasive technique where surgeons utilize robotic systems to conduct heart procedures. These systems enhance precision, flexibility, and control through small incisions, leading to less pain, a reduced risk of infection, shorter hospital stays, and faster recovery times compared to traditional open-heart surgery.

The key products and services in robotic cardiology surgery include robotic systems, instruments and accessories, maintenance services, and system services. Robotic systems are sophisticated, computer-assisted platforms used by surgeons for minimally invasive procedures. Equipment types encompass robot machines, navigation systems, planners, and simulators, among others. These technologies are employed by various end-users, including hospitals and research centers.

The robotic cardiology surgery market research report is one of a series of new reports that provides robotic cardiology surgery market statistics, including robotic cardiology surgery industry global market size, regional shares, competitors with a robotic cardiology surgery market share, detailed robotic cardiology surgery market segments, market trends, and opportunities, and any further data you may need to thrive in the robotic cardiology surgery industry. This robotic cardiology surgery market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The robotic cardiology surgery market consists of revenues earned by entities by providing services such as robotic hybrid procedures, robotic atrial septal defect (ASD) repair, and robotic tricuspid valve repair services. The market value includes the value of related goods sold by the service provider or included within the service offering. The robotic cardiology surgery market also includes sales of coronary artery bypass grafting systems, robotic surgical systems, and remote navigation systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.